12,144 Shares in Stryker Co. (NYSE:SYK) Bought by WINTON GROUP Ltd

WINTON GROUP Ltd purchased a new stake in Stryker Co. (NYSE:SYK) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 12,144 shares of the medical technology company’s stock, valued at approximately $4,372,000.

A number of other institutional investors also recently modified their holdings of the company. Kohmann Bosshard Financial Services LLC acquired a new stake in Stryker in the 4th quarter valued at approximately $25,000. Dunhill Financial LLC grew its stake in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares in the last quarter. Rakuten Securities Inc. lifted its position in shares of Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after purchasing an additional 68 shares in the last quarter. Centricity Wealth Management LLC acquired a new position in Stryker during the fourth quarter worth $30,000. Finally, BankPlus Trust Department bought a new position in Stryker in the fourth quarter valued at $33,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Performance

NYSE:SYK opened at $367.34 on Thursday. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The stock has a 50 day simple moving average of $384.74 and a 200 day simple moving average of $374.29. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The stock has a market cap of $140.17 billion, a P/E ratio of 47.34, a PEG ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the firm earned $3.46 EPS. Research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.91%. Stryker’s dividend payout ratio is presently 43.30%.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on SYK. Canaccord Genuity Group increased their price objective on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Royal Bank of Canada increased their price target on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research report on Wednesday, January 29th. Truist Financial raised their price target on Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a research note on Thursday, January 30th. Citigroup reissued a “buy” rating and issued a $450.00 target price on shares of Stryker in a research note on Wednesday, February 26th. Finally, JPMorgan Chase & Co. upped their price target on shares of Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $421.90.

Insider Activity

In related news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.